Please use this identifier to cite or link to this item:
Title: T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.
Authors: Raspollini, Maria Rosaria
Luque, Rafael J
Menendez, Carmen Luz
Bollito, Enrico
Brunelli, Matteo
Martignoni, Guido
Montironi, Rodolfo
Cheng, Liang
Blanca, Ana
Baroni, Gianna
Minervini, Andrea
Lopez-Beltran, Antonio
Keywords: Bladder cancer;E-cadherin;Progression;Survivin;T1;Topoisomerase-IIα;p16
metadata.dc.subject.mesh: Aged
Antigens, CD
Antigens, Neoplasm
Biomarkers, Tumor
Carcinoma, Papillary
Cyclin-Dependent Kinase Inhibitor p16
DNA Topoisomerases, Type II
DNA-Binding Proteins
Disease-Free Survival
Inhibitor of Apoptosis Proteins
Kaplan-Meier Estimate
Neoplasm Grading
Predictive Value of Tests
Proportional Hazards Models
Reproducibility of Results
Time Factors
Treatment Outcome
Tumor Burden
Urinary Bladder Neoplasms
Issue Date: 26-Jul-2016
Abstract: High-grade papillary urothelial carcinoma with subepithelial connective tissue invasion (T1HG) is an aggressive disease at high risk of progression after transurethral resection/Bacillus Calmette-Guerin standardized therapy. The European Organization for Research and Treatment of Cancer has identified T1HG bladder carcinoma that is single and ≤3 cm in the largest dimension at first diagnosis as a category in which the prognosis cannot be further stratified based on conventional criteria. This category may benefit from biomarker analysis as a valuable tool to determine the patient's outcome. To further the issue of biomarkers in predicting aggressiveness in single T1HG bladder carcinoma ≤3 cm in greatest dimension at first diagnosis, we have conducted a validation study of the biomarker risk score set previously reported by our group. The study set included immunohistochemical detection of galectin-3, CD44, E-cadherin (E-CAD), CD138, p16, survivin, HYAL-1, and topoisomerase-IIα in 92 randomly selected specimens at participating institutions. Topoisomerase-IIα expression was identified as a predictor of disease-free survival. p16, survivin, and E-CAD expression predicted progression-free survival, but p16 and E-CAD also predicted overall survival. The current study validates a panel of immunohistochemical markers with the potential of being implemented in practice and supports the use of biomarkers in predicting aggressiveness in patients with first diagnosis of single T1HG bladder carcinoma ≤3 cm in greatest dimension and therefore in identifying patients who need closer surveillance or earlier aggressive treatment.
metadata.dc.identifier.doi: 10.1016/j.humpath.2016.06.022
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.